Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist

OBJECTIVETo assess the efficacy and safety of the novel angiotensin II antagonist olmesartan medoxomil in patients with mild to moderate essential hypertension, using a meta-analysis of the combined database from seven US and European clinical trials. DESIGNStudies were randomized, double-blind, pla...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of hypertension 2001-06, Vol.19 Suplement 1 (1), p.S41-S48
Hauptverfasser:	Püchler, Kurt, Laeis, Petra, Stumpe, Klaus O
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiotensin II - antagonists & inhibitors Antihypertensive Agents Blood Pressure Dose-Response Relationship, Drug Humans Imidazoles - adverse effects Imidazoles - therapeutic use Incidence Olmesartan Medoxomil Randomized Controlled Trials as Topic Safety Tetrazoles - adverse effects Tetrazoles - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!